Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma

Thyroid

Volumn 14, Issue 10, 2004, Pages 848-852

  Magalhães, Patricia K R ^a   De Castro, Margaret ^a   Elias, Lucila L K ^a   Soares, Edson G ^a   Maciel, Léa M Z ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FAMILIAL DISEASE; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTO ONCOGENE; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA;

ADULT; CARCINOMA, MEDULLARY; EXONS; HUMANS; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; ONCOGENE PROTEINS; PHENOTYPE; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 8444249623     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2004.14.848     Document Type: Article

References (27)

1. Hazard JB, Hawk WA, Crile Jr G 1959 Medullary (solid) carcinoma of the thyroid - A clinicopathologic entity. J Clin Endocrinol Metab 19:152-161.
2. Raue F, Frank-Raue K, Grauer A 1994 Multiple endocrine neoplasia type 2. Clinical features and screening. Endocrinol Metab Clin North Am 23:137-156.
3. Wohllk N, Cote GJ, Evans DB, Goepfert H, Ordonez NG, Gagel RF 1996 Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocrinol Metab Clin North Am 25:1-25.
4. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJM, Gagel RF, Takai SI, Noll WW, Fink M, Raue F, Lacroix A, Thibodeau SN, Frilling A, Ponder BAJ, Eng C 1995 International RET mutation consortium. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: Report of the International RET mutation consortium. J Intern Med 238:343-346.
5. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Van Amstel HKP, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579.
6. Lips CJM 1998 Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease. J Intern Med 243:589-594.
7. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri R, Libroia A, Lips CJM, Lombardi G, Mannelli M, Pacini F, Ponder BAJ, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells Jr AS, Marx SJ 2001 Consensus: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671.
8. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells AS Jr 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856.
9. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460.
10. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppener JWM, Van Amstel HKP, Romeo G, Lips CJM, Buys CHCM 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376.
11. Mulligan LM, Eng C, Healey CS 1994 Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6:70-74.
12. Machens A, Gimm O, Hinze R, Höppner W, Boehm BO, Dralle H 2001 Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: Oncological features and biochemical properties. J Clin Endocrinol Metab 86:1104-1109.
13. Niccoli-Sire P, Murat A, Rohmer V, Frank S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S, Kottler M, Morange S, Conte-Devolx B and The French Calcitonin Tumors Study Group (GETC) 2001 Familial medullary thyroid carcinoma with noncysteine RET mutations: Pheno-type-genotype relationship in a large series of patients. J Clin Endocrinol Metab 86:3746-3753.
14. Borrego S, Sáez ME, Ruiz A, Gimm O, López-Alonso M, Antiñolo G, Eng C 1999 Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 36:771-774.
15. Sancandi M, Ceccherini I, Costa M, Fava M, Chen B, Wu Y, Hofstra R, Laurie T, Griffths M, Burge D, Tam PKH 2000 Incidence of RET mutations in patients with Hirschsprung's disease. J Pediatr Surg 35:139-143.
16. Wiench M, Gubala E, Wloch J, Lisowska K, Krassowski J, Scieglinska D, Fiszer-Kierzkowska A, Lange D, Kula D, Zeman M, Roskosz J, Kukulska A, Jarzab B 2001 Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol 19:1374-1380.
17. Miller SA, Dykes DD, Polesky HF 1988 A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:12-15.
18. Vieira AEF, Mello MP, Elias LLK, Lau IF, Maciel LMZ, Moreira AC, Castro M 2002 Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A. Horm Metab Res 34:1-5.
19. Ito S, Iwashita T, Asai N, Murakami H., Iwata Y, Sobue G, Takahashi M 1997 Biological properties of RET with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma and Hirschsprung's disease phenotype. Cancer Res 57:2870-2872.
20. Hansford JR, Mulligan LM 2000 Multiple endocrine neoplasia type 2 and RET: From neoplasia to neurogenesis. G. J Med Genet 37:817-827.
21. Hofstra RMW, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CHCM 1997 A novel point mutation in the intracellular domain of the RET proto-oncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82:4176-4178.
22. Berndt I, Reuter M, Sailer B, Frank-Raue K, Groth P, Grussendorf F, Raue F, Ritter MM, Höppner W 1998 A new hot spot for mutations in the ret proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770-774.
23. Nilsson O, Tisell LE, Jansson S, Ahlman H, Gimm O, Eng C 1999 Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation. JAMA 281:1587-1588.
24. Ceccherini I, Romei C, Barone V, Pacini F, Martino E, Loviselli A, Pinchera A, Romeo G 1994 Identification of the Cys634 → Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis. J Endocrinol Invest 17:201-204.
25. Gimm O, Neuberg DS, Marsh DJ, Dahia PLM, Hoang-Vu C, Raue F, Hinze R, Dralle H, Eng C 1999 Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 18:1369-1373.
26. Ruiz A, Antiñolo G, Fernández RM, Eng C, Marcos I, Borrego S 2001 Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clin Endocrinol (Oxf) 55:399-402.
27. Lombardo F, Baudin E, Chiefari E, Arturi F, Bardet S, Caillou B, Conte C, Dallapiccola B, Giuffrida D, Bidart J, Schlumberger M, Filetti S 2002 Familial medullary thyroid carcinoma: Clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab 87:1674-1680.